أرسل هذا في رسالة قصيرة: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

 _    _      ___    __    __   __   __    _____   
| || | ||   / _ \\  \ \\ / //  \ \\/ //  |__  //  
| || | ||  / //\ \\  \ \/ //    \ ` //     / //   
| \\_/ || |  ___  ||  \  //      | ||     / //__  
 \____//  |_||  |_||   \//       |_||    /_____|| 
  `---`   `-`   `-`     `        `-`'    `-----`